Text Size
10 studies found for:    siltuximab

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Recruiting A Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Patients With Multicentric Castleman's Disease
Condition: Multicentric Castleman's Disease
Intervention: Drug: Siltuximab
2 Terminated A Phase 1 Study of CNTO 328 (Siltuximab) in Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Siltuximab
3 Withdrawn A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Placebo, Velcade and dexamethasone;   Biological: Siltuximab, Velcade and dexamethasone
4 Terminated A Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Patients With International Prognostic Scoring System Low- or Intermediate-1-Risk Myelodysplastic Syndrome
Condition: Myelodysplastic Syndrome
Interventions: Drug: Siltuximab + BSC;   Drug: Placebo + BSC
5 Active, not recruiting A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma
Conditions: Monoclonal Gammopathy of Undetermined Significance;   Multiple Myeloma;   Plasma Cell Neoplasm
Intervention: Biological: Siltuximab
6 Active, not recruiting Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM)
Condition: Myeloma
Interventions: Drug: Lenalidomide;   Drug: Bortezomib;   Drug: Siltuximab;   Drug: Dexamethasone;   Behavioral: Questionnaires
7 Recruiting A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Condition: High-risk Smoldering Multiple Myeloma
Interventions: Drug: Siltuximab;   Drug: Placebo
8 Completed A Safety and Efficacy Study of Siltuximab (CNTO 328) in Participants With Metastatic Hormone-Refractory Prostate Cancer (HRPC)
Condition: Cancer, Prostate
Interventions: Drug: Mitoxantrone;   Biological: CNTO 328
9 Completed
Has Results 		S0354, Anti-IL-6 Chimeric Monoclonal Antibody in Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
Condition: Prostate Cancer
Intervention: Biological: CNTO 328
10 Withdrawn S0351, CNTO 328 in Treating Patients With Unresectable or Metastatic Kidney Cancer
Condition: Kidney Cancer
Intervention: Biological: CNTO 328
To Top

† Indicates status has not been verified in more than two years